Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male and female subjects with MUC1+ malignancies in patients with no available curative treatment options who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
10 participants in 1 patient group
Loading...
Central trial contact
Lin Yang, Ph.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal